UNSPSC 51262607: Napamezole hydrochloride

This classification denotes a serotonin agonist and alpha-adrenergic blocking agent with the molecular formula C14H16N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DTN86H1ZWK, chemically known as 2-((3,4-dihydro-2-naphthyl)methyl)-2-imidazoline hydrochloride but more generally known as napamezole hydrochloride, which bears US NIH Compound Identifier 3033727. Most nations, for tariff and trade purposes, schedule napamezole hydrochloride under HS 29332990 and SITC 51573.

As of Q4 2014, NAPAMEZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Napamezole hydrochloride bears US NLM identifiers UMLS ID C2825583 and NCI Concept Code C81333. SMILES: C1CCC2C(C1)CCC(=C2)CC3=NCCN3.CL.

UNSPSC 51262607 Napamezole hydrochloride is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent activity shows a mismatch between the code's nominal scope and actual purchasing patterns. The single concrete opportunity visible in the recent record—Seminole County, Florida's IFB for naloxone and drug deactivation systems—centers on opioid-reversal medications and harm-reduction equipment rather than napamezole hydrochloride specifically. A second opportunity from the Texas Health and Human Services Commission represents a preliminary RFI exploring direct-to-manufacturer pharmacy contracting models but does not specify product lines or purchasing volumes. The code shows limited recent solicitation activity; state and local buying under this code appears sporadic and heavily driven by public health initiatives tied to opioid response or community health programs rather than routine pharmaceutical procurement.

Seminole County, Florida posted the most concrete recent opportunity: IFB 60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023, and potentially funded through FEMA. The Texas HHS Commission's RFI (HHS0017013), posted April 3, 2026, solicits vendor capabilities for direct-to-manufacturer prescription programs but remains exploratory and does not commit to specific product volumes or timeframes. Geographic activity centers on Florida and Texas, with no indication of broader regional or national purchasing patterns under this code. The lack of substantial recent opportunity volume and the mismatch between the code name and the actual work being bought suggest this code may see limited state and local procurement activity or may be misclassified in existing solicitations.